CME Snapshot™

Emerging Therapies and Changing Architecture of HIV Management

Clinical Practice Guidelines

Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living With HIV.

US Department of Health and Human Services, 2018.

Laboratory Testing for the Diagnosis of HIV Infection: Updated Recommendations.

Centers for Disease Control and Prevention, 2018.

Updated PrEP Clinical Practice Guideline and PrEP Clinical Providers’ Supplement—2017.

Centers for Disease Control and Prevention, 2017.

Clinical Resources

American Academy of HIV Medicine | Supporting the HIV Care Provider and the Profession.

Database of Antiretroviral Drug Interactions.

HIV Insite. University of California, San Francisco.

HIV Drug Interactions.

University of Liverpool (Web site), 2018.

PrEP Kit.

AIDS United, 2015.

Patient Resources

HIV Risk Reduction Tool.

Centers for Disease Control and Prevention, 2017.

Centers for Disease Control and Prevention (CDC): HIV Basics.

The CDC is a division within the US Department of Health and Human Services (DHHS), the principal agency for protecting the health of all Americans. This comprehensive site provides extensive links to topics across the HIV-care continuum, including preexposure prophylaxis (PrEP).

Pill-Reminder Smartphone Apps (Free).

Mango Health – Medicine Manager, Pill Reminder for iPhone.

Mango Health for Android.

Medisafe Pill Reminder, Rx, & Medicine Tracker for iPhone.

Medisafe Meds & Pill Reminder for Android.

Positively Aware.

Positively Aware, created by TPAN (Test Positive Aware Network), is a source of HIV-treatment news for consumers, as well as an educational tool for HIV caregivers. The site features PrEP resources, including videos for men who have sex with men and transgender people.

PrEP for U.S. Women: A Collection of Resources.

HIVE (Website).
HIVE provides preconception and prenatal care and resources for women and couples affected by HIV.

Suggested Readings

Superior efficacy of dolutegravir (DTG) plus 2 nucleoside reverse transcriptase inhibitors (NRTIs) compared with lopinavir/ritonavir (LPV/RTV) plus 2 NRTIs in second-line treatment: interim data from the DAWNING study.

Aboud M, et al. 9th International AIDS Society Conference. July 23-26, 2017; Paris, France. Abstract TUAB0105LB.

Removing the stigma of HIV.

American Pharmacists Association, 2017.

Effect of HIV antibody VRC01 on viral rebound after treatment interruption.

Bar KJ, et al. N Engl J Med. 2016;375(21):2037-2050.

Frequency of HIV testing and time from infection to diagnosis improve.

Centers for Disease Control and Prevention, 2017.

Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1–infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial.

Ciaffi L, et al. Lancet HIV. 2017;4(9):e384-e392.

Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial.

Gallant J, et al. Lancet. 2017;390(10107):2063-2072.

Risks of cardiovascular or central nervous system adverse events and immune reconstitution inflammatory syndrome, for dolutegravir versus other antiretrovirals: meta-analysis of randomized trials.

Hill AM, et al. Curr Opin HIV AIDS. 2018;13(2):102-111.

Initiation of antiretroviral therapy in early asymptomatic HIV infection.

The INSIGHT START Study Group. N Engl J Med. 2015;373(9):795-807.

Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies.

Llibre JM, et al. Lancet. 2018;391(10123):839-849.

Phase 3 study of fostemsavir in heavily treatment-experienced HIV-1–infected participants: day 8 and week 24 primary efficacy and safety results (BRIGHTE Study, formerly 205888/AI438-047).

Kozal M, et al. 16th European AIDS Conference. October 25-27, 2017; Milan, Italy. Abstract PS8/5.

Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial.

Margolis DA, et al. Lancet. 2017;390(10101):1499-1510.

Resistance against integrase strand transfer inhibitors and relevance to HIV persistence.

Mesplède T, Wainberg MA. Viruses. 2015;7(7):3703-3718.

Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial.

Molina JM, et al. Lancet HIV. 2018;5(5):e211-e220.

Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial.

Orkin C, et al. Lancet HIV. 2018;5(1):e23-e34.

The role of substance use and mental health problems in medication adherence among HIV-infected MSM.

White JM, et al. LGBT Health. 2014;1(4):319-322.

Pooled week 48 efficacy and baseline resistance: B/F/TAF in treatment-naïve patients.

White K, et al. 25th Conference on Retroviruses and Opportunistic Infections (CROI), 2018. March 4−7, 2018; Boston, MA. Abstract 532.

Evaluations And Treatment of Virologic Failure

Emerging Concepts

The Changing Architecture of HIV Care

Review of Novel Agents and Approaches

Relevant Resources

PrEP for Your Patients’ Needs

The PCPs Role in Preventing HIV

Value-Based HIV Formularies

Optimizing Use of Clinical Evidence & Pharmacoeconomic Models in Managed Care

Hepatitis C is Curable

Got it? Treat it!

Real-World Issues in HIV Prevention & Treatment

The Critical Role of the Community Pharmacist


Bringing Local Communities Together to Eliminate Coinfection Through Knowledge and Partnerships.

Evolving Models of HIV Care

Volume 1: Rapid ART Initiation: A New Addition to the HIV-Care Tool Box

Updates in HCV Screening and Treatment

Key Issues Impacting OB/GYN Practice

Clinical Issues in Chronic Liver Disease

Hot Topics in HBV, HCV, and NASH

Evolving Models of HIV Care

Volume II: Expanding Evidence for the Role of Rapid ART Initiation in HIV Practice

Assessing Your Patients for HCV and HIV

Why It Matters in OB/GYN Practice Today

HIV as a Chronic Disease

A Treater’s Guide to Optimizing Care in the Aging Patient with Comorbidities

The Pursuit of Hepatitis C Elimination

How the Pharmacist Can Make a Difference

Trends in Infectious Diseases: Updates on Treatment & Prevention Strategies for HIV and HCV

Understanding the Growing Syndemic — Opioids, HCV, and HIV

Stepping Up to the Challenge

The PCP’s Role in HCV Elimination

The Changing Landscape of HIV Prevention

What the Pharmacist Needs to Know about PrEP

Evolving Models of HIV Care (Volume 3)

The Rapid ART Standard of Care: From Evidence to Healthcare Equity

HIV Updates for Pharmacy Practice

Maximizing Your Role to Impact Patient Outcomes


Building Bridges to Reach People Who Inject Drugs With the Goal to Eliminate HCV

Case Challenges in HIV Medicine

Benefits, Barriers, & Best Practices in an Advancing Field

Challenges and Opportunities in HIV

Practical Solutions Across the Spectrum of Care

A Critical Appraisal of Non-Invasive Technologies in NASH

Informing the Future of NASH Diagnosis and Assessment

Expanding HIV Prevention in Colorado—and Nationwide

A PEP/PrEP Training Guide for Pharmacists

Treating Hepatitis C in the Primary Care Setting

A Critical Step Toward HCV Elimination

Honing Clinical Skills in HIV Treatment

Considering the Patient, the Provider, and the Science

Hot Topics in HCV

A Multidisciplinary Online Mini-Curriculum

Clinical Issues in COVID-19

Debates and Discussions about Monoclonal Antibody Therapies

Minimizing Patient Risks From COVID-19

An Update on Monoclonal Antibody Therapies

Treating Hepatitis C in the Primary Care Setting

Establishing Clinical Readiness Through Mentored Learning

Clinical Updates in COVID-19

Recent Developments in Anti-SARS-CoV-2 Monoclonal Antibodies for Treatment

Monoclonal Antibodies for COVID-19

An Update on Best Practices

Monoclonal Antibodies for COVID-19

New Avenues to Pre-Exposure Prophylaxis

Virologic Failure in HIV

An Updated Clinician’s Guide to Assessment and Management

Applying HIV Advances in Practice

What the Pharmacist Needs to Know

Buffing Up on New and Emerging ART

A Look at the Changing HIV Playing Field

Pharmacy PrEP Education

A “How To” Series Spanning Policy to Practice


Building Bridges to Reach People who Inject Drugs with the Goal of Employing PrEP for HIV Prevention

Long-Acting Injectable PrEP:

Bringing HIV Prevention to a New Level

PrEParing to End the Epidemic

Optimizing HIV Prevention in Primary Care

A Call to Action

Monoclonal Antibodies for the Prevention and Treatment of COVID-19

Answers to Everyday Practice Challenges in HIV Medicine

A Phone-a-Friend CME Series – Volume 2

What’s New in the Management of COVID-19

Incorporating New Data and Updated Guidelines Into Daily Practice